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Abstract
Introduction: The present review of Alzheimer’s disease (AD) rating scales aims to outline the need for a new
rating scale to be used in routine clinical practice for long-term medical care of AD patients. An ideal scale would
be: 1) practical, easy and quick to administer for an experienced clinician; 2) validated for AD; 3) multi-domain:
covering the AD-relevant areas of cognition, activities of daily living, behavior, communication/social interaction,
and quality of life; 4) applicable to all AD severity stages; 5) able to monitor disease progression; and 6) sensitive to
measure therapy effects.
Methods: The National Library of Medicines’ MEDLINE database was searched for the years 1981 to September
2008, using a set of keywords aiming to select instruments which cover at least some of the requirements for an
ideal practical AD scale for therapy evaluation. Measures for AD staging and screening tests were not considered
for review.
Results: Of 1,902 articles resulting from the literature search, 68 relevant AD scales were identified. Most of them
were scales that predominantly measure the severity of major dysfunctions in particular AD domains. Only five
scales met some of the requirements for a practical multi-domain AD scale, but did not possess all required
characteristics.
Conclusions: Despite the multitude of AD scales for various purposes, there remains a need for a new multi-
domain and easy to administer AD scale for assessment of disease progression and response to therapy in daily
medical practice.
Introduction
Alzheimer’s disease (AD), together with other forms of
dementia, represents a major challenge for health care
systems with aging populations. AD is associated with
neurodegenerative changes which compromise not only
cognitive functioning but also lead to a decline in func-
tional abilities and induce a spectrum of psychological
or behavioral symptoms [1]. Many efforts are currently
undertaken to investigate AD pathology and develop
appropriate treatment strategies. These strategies focus
on long-term preservation of cognitive and functional
abilities or slowing down disease progression along with
reducing behavioral symptoms and maintaining the
patient’s quality of life [2,3]. As long as there is no treat-
ment leading to reversal or stopping of disease progres-
sion, an amelioration of the disease symptoms, which
may delay institutionalization, as well as a reduction of
caregiver burden and costs, are realistic treatment goals
today.
Rating scales are essential tools for AD diagnosis, sta-
ging, assessment and careful monitoring of AD symp-
toms as well as for evaluation of treatment effects. For
decades most AD assessments were predominantly
focused on cognition, which is the lead symptom in AD.
Nevertheless, it has been realized that the symptoms
more relevant to a patient’s quality of life, caregiver bur-
den and institutionalization are functional and beha-
vioral symptoms [4]. In the 1990 s, the development of
new measures was requested by regulatory authorities to
demonstrate clinically relevant treatment effects on
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sently, rating scales for assessment of both behavior and
functioning, besides cognition, and evaluation of a
patient’s global impression are standard outcome mea-
sures in AD clinical trials [5]. Also, scales for assessment
of advanced AD patients have been developed [6,7],
demonstrating the considerably retained abilities of such
patients and refuting the belief that patients beyond the
moderate stage are not accessible to pharmacological
and non-pharmacological treatment. Nevertheless, a
need for better instruments, which are more sensitive to
disease staging or changes over time, has been acknowl-
edged by the European Medicines Agency [5] and
recently confirmed by reviewing the outcome measures
used in current clinical trials [8].
Despite the extensive development of rating scales for
AD research, the overall assessment of disease progres-
sion in routine medical practice remains lengthy and
complicated. One reason for that is the need for using a
set of scales to assess all AD-relevant symptom domains,
which is usually an arduous procedure for both physi-
cian and patient/caregiver. Also, most rating scales are
not applicable to all AD severity stages, that is, many
assessment tools are not consistently sensitive to mea-
sure disease progression or therapy effects across the
whole patient population.
To discuss the use of current rating scales for evalua-
tion of AD therapy in AD daily medical practice, an
expert panel group composed of the authors of this arti-
cle was set up (14 and 15 September 2007). The panel
assumed that an ideal AD instrument for daily medical
practice should cover all requirements presented in
Table 1.
In this paper, we provide a brief overview on AD
scales developed for assessment of cognition, daily func-
tion, global impression, behavior, quality of life as well
as communication and social interaction, with a focus
on their applicability in daily medical practice for moni-
toring disease progression and therapy effects. The
review does not pretend to have included all scales
available and used in AD clinical practice so far. It
rather summarizes individual scales for the various AD
symptom domains and points to the need for a new
multi-domain AD scale to enable disease assessment
over time in daily medical practice.
Materials and methods
To discover available AD scales covering the require-
ments listed in Table 1, we performed a systematic lit-
erature search, employing the National Library of
Medicines’ MEDLINE database. For this purpose, an
appropriate search algorithm was established: i) to
ensure the inclusion of records about tools used in the
assessment of AD (keywords: Alzheimer (’s disease),
scale, assessment, rating/rater, questionnaire); ii) to
avoid the inclusion of records about measures only for
AD diagnosis and staging (keywords: efficacy, outcome,
disease progression); iii) to include records on aspects
considered neglected in many AD scales (keywords:
quality of life, communication, social interaction/activ-
ities). Only documents in English, French, German, Ita-
lian, and Spanish were considered. Measures specialized
on specific topics (for example, assessment of visuospa-
tial functioning, verbal learning) or not developed for
AD, dementia, or geriatric patients were omitted. Com-
puterized instruments were not considered due to the
technical demands often deemed incompatible with
daily practice use. Caregiver burden tools were also
excluded since only scales for assessment of AD symp-
toms were of interest for this literature review.
Two independent reviewers assessed each selected
article independently and with regard to its suitability
and quality. In cases when the reviewers could deter-
mine from the abstract that the selection criteria were
not met, the respective articles were rejected; or when a
paper could not be rejected with certainty from the
abstract, the full text article was obtained and evaluated.
In addition, the references included in the selected arti-
cles were evaluated to identify further possible docu-
ments of interest. Any differences between the
reviewers’ results were resolved by discussion.
Each rating scale identified from the selected articles
was compared with the requirements for a multi-domain
AD scale for daily medical practice given in Table 1.
Results and discussion
Our systematic literature search revealed a total of 1,902
articles published from July 1981 to September 2008. By
screening the results, special attention was paid to iden-
tification of scales containing items of several AD symp-
tom domains, excluding instruments mainly used for
Table 1 Characteristics of a multi-domain AD scale for daily medical practice
1) Easy and quick administration by an experienced clinician; about 10 minutes administration time
2) Reliable and valid for AD
3) Covering the AD relevant areas cognition, activities of daily living, behavior, communication and social interaction, and quality of life
4) Applicable to all AD severity stages (with minimal floor and ceiling effects)
5) Useful for monitoring of disease progression in clinical practice
6) Sensitive to measure therapy effects
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editorials, meta-analyses, or studies published in English,
French, German, Italian, and Spanish languages were
considered. Most of the selected articles referred to vali-
dated and AD-specific tools developed over the last
three decades to assess the regulatory relevant AD-
symptom complexes: cognition, activities of daily living
(ADL), and global changes. The rest of the articles
revealed instruments for assessment of behavior,
patient’s quality of life, and communication and social
interaction. Out of all selected articles, 68 relevant AD
scales were identified. An overview of the scales grouped
by AD symptom domains is provided in Table 2.
Cognition
A total of nine instruments for assessment of cognitive
impairment were identified by the literature search
(Table 2). They comprise measures of cognition in
patients with mild to severe AD, which have been used
in different clinical settings. The most often used scale
for assessment of cognition is the Mini-Mental State
Examination (MMSE). It was designed as a practical
tool for grading the cognitive state of patients [9]. The
target population is patients with cognitive disturbances
derived from dementia syndromes, affective or personal-
ity disorders. The scale comprises 11 questions or sim-
ple tasks concerning orientation, memory, attention and
language to evaluate the patient’s cognitive state. Other
mental or behavioral aspects are excluded, thus it
requires only 5 to 10 minutes for a trained rater to
administer it. The MMSE is the standard staging and
assessment tool in AD. Given the widespread use of the
MMSE, clinical and research findings can be easily com-
pared. However, there are several drawbacks limiting the
utility of MMSE. Some items are judged to be relatively
easy and therefore patients with mild AD are not sensi-
tively evaluated due to ceiling effects [10]. In contrast,
floor effects limit the application to patients with more
advanced AD. Furthermore, using MMSE for staging of
AD severity neglects other more patient- and caregiver-
relevant domains of AD assessment, such as function
and behavior. Also, measurement error, practice effect,
or other factors such as age, education or cultural back-
ground may impair the sensitivity and validity of the
assessment of disease progression and pharmacological
treatment effects [11-13].
Another scale used in almost all clinical trials on
symptomatic AD therapy is the Alzheimer’sD i s e a s e
Assessment Scale (ADAS). It was designed to assess
both cognitive and non-cognitive AD-specific symptoms
[14]. The cognitive subscale, ADAS-Cog, is a standard
tool in pivotal clinical trials to detect therapeutic efficacy
in cognition. It consists of 11 subtests related to mem-
ory, praxis, and language. The non-cognitive subscale of
ADAS comprises 10 items evaluating mood and beha-
vioral changes. Depending on the AD severity stage of a
patient, the administration of ADAS-Cog takes 30 to 45
minutes. In contrast to the ADAS-Cog, the non-cogni-
tive subscale is rarely used. The ADAS-Cog appears to
be most adequate for patients with moderate AD.
Patients with mild cognitive impairment and mild AD
are subject to ceiling effects and patients in advanced
AD stage are subject to floor effects, in part due to
eroding language abilities. In general, the measurement
error of ADAS-Cog limits disease progression monitor-
ing, especially in short-term evaluations [15]. As the ori-
ginal ADAS-Cog neglects some cognitive functions,
such as planning and executive function, several addi-
tional subtests have further been developed [16].
As the standard cognitive tools MMSE and ADAS-
Cog are not considered sensitive enough to measure
treatment effects in early disease stages optimally, a
Neuropsychological Test Battery (NTB) has recently
been developed to fill this gap [17]. The NTB is
designed to emphasize the assessment of memory and
executive function in patients with mild to moderate
AD, combining nine previously validated cognitive tests.
In addition, it provides an index of global cognitive
function in mild AD patients. The completion of the
NTB takes about 40 minutes.
To enable the assessment of cognition in later AD
stages, the Severe Impairment Battery (SIB) was devel-
oped [6,18]. The SIB, rather than rating erroneous per-
formance, relies on the appraisal of preserved abilities in
nine cognitive domains: social interaction, memory,
orientation, language, attention, praxis, visuospatial abil-
ities, constructional abilities and orientation to name. A
maximum of 30 minutes is required for administration.
A short SIB version [19] and a version based on the
SIB-language domain, SIB-L [20], have also been devel-
oped. Another brief, reliable and valid measure of cogni-
tive function in severely demented AD patients is the
Severe Cognitive Impairment Rating Scale [21]. For sta-
ging the severity of cognitive deficits and assessing the
benefits of AD therapy, the Syndrom-Kurztest [22] has
extensively been used in earlier clinical trials. It is well
accepted by patients, hospital clinicians, and general
practitioners due to its brevity and simplicity.
Activities of daily living (ADL)
Among numerous ADL scales available for several dec-
ades to rate the degree of disability or the need for
assistance in geriatric population, 17 ADL instruments
were identified by the literature search presented here
(Table 2). In general, basic ADL, including self-mainte-
nance skills such as walking, feeding, and dressing, are
distinguished from the instrumental activities of daily
living (IADL), addressing more complex activities such
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Aspects of AD
disorder
Abbreviation Full name
Cognitive
Impairment
ADAS-Cog Alzheimer’s Disease Assessment Scale - Cognitive Subscale [14] Rosen et al.1984
BIMC Blessed Information-Memory-Concentration Test [77] Blessed et al. 1968
CAMCOG Cambridge Cognitive Examination [78] Grevett & O’Brien 2002
MDRS Mattis Dementia Rating Scale [79] Mattis 1976
MMSE Mini-Mental State Examination [9] Folstein et al. 1975
NTB Neuropsychological Test Battery [17] Harrison et al. 2007
SCIP Severe Cognitive Impairment Profile [21] Peavy et al. 1996
SIB Severe Impairment Battery [6] Saxton & Swihart 1989
SKT Syndrom-Kurztest [22] Erzigkeit 1989
Activities of Daily
Living
ADL-PI Activities of Daily Living-Prevention Instrument [31] Galasko et al. 2006
ADLQ Activities of Daily Living Questionnaire [80] Johnson et al. 2004
ADCS-ADL19/
23
Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory 19- or
23-item Scale [25]
Galasko et al. 1997
B-ADL Bayer Activities of Daily Living Scale [30] Hindmarch et al. 1998
Bristol ADL Bristol Activities of Daily Living Scale [81] Bucks et al. 1996
BANS-S Bedfords Alzheimer’s Nursing Severity Scale [82] Bellelli et al. 1997
Barthel ADL Barthel Activities of Daily Living Index Scale [83] Mahoney & Barthel 1965
DAD Disability Assessment for Dementia [26] Gelinas et al. 1999
GERRI Geriatric Evaluation by Relative’s Rating Instrument [84] Schwartz 1983
IADL Instrumental Activities of Daily Living Scale [24] Lawton & Brody 1969
IDDD Interview for Deterioration in Daily Living Activities in Dementia [27] Teunisse et al. 1991
Katz ADL The Katz Index of Independence in Activities of Daily Living [23] Katz et al. 1963
PGDRS Psychogeriatric Dependency Rating Scales [85] Wilkinson & Graham-
White 1980
RDRS Rapid Disability Rating Scale [29] Linn 1976
PSMS Physical Self-Maintenance Scale [24] Lawton & Brody 1969
SMAF Functional Autonomy Measurement System [28] Hebert et al. 2001
Weintraub
ADL
Weintraub Activities of Daily Living Scale [86] Weintraub 1986
Global Impression ADCS-CGIC Alzheimers’ Disease Cooperative Study - Clinical Global Impression of Change [38] Schneider et al. 1997
CDR Clinical Dementia Rating Scale [35] Hughes et al. 1982
CGI Clinical Global Impression [34] Guy 1976
CIBI Clinical Interview Based Impression (Parke-Davis) [87] Knopman et al. 1994
FAST The Functional Assessment Staging [37] Reisberg 1988
GDS Global Deterioration Scale [36] Reisberg 1982
HDR Hierarchic Dementia Rating Scale [88] Cole & Dastoor 1983
NYU CIBIC-
Plus
The New York University - Clinician’s Interview-Based Impression of Change - Plus
Caregiver Input [39]
Reisberg & Ferris 1994
Behavior/
Neuropsychology
AMS Alzheimer’s Mood Scale [52] Tappen & Williams 1999
IA Apathy Inventory [49] Robert et al. 2002
BEAM-D Behavioral and Emotional Activities Manifested in Dementia [89] Sihna et al. 1992
BEHAVE-AD Behavioral Pathology in Alzheimer’s Disease Rating Scale [40] Reisberg et al. 1987
BPRS Brief Psychiatric Rating Scale [41] Overall & Gorham 1962
CERAD-BRSD Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for
Alzheimer’s Disease [45]
Tariot et al. 1995
CMAI Cohen-Mansfield Agitation Inventory [47] Cohen-Mansfield 1986
CSDD Cornell Scale for Depression in Dementia [51] Alexopoulos et al. 1988
DBD Dementia Behavior Disturbance Scale [46] Baumgarten et al. 1990
DMAS Dementia Mood Assessment Scale [50] Sunderland et al. 1988
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Page 4 of 13as shopping, cooking, handling finances, or using the
telephone or transportation. The oldest and most widely
used tools to assess functioning are the Katz Index of
ADL, which covers six basic ADL (bathing, dressing, toi-
leting, transfer, continence, feeding) [23], and the ADL/
IADL scales developed by Lawton and Brody (1969),
which contain both basic ADL and IADL [24].
The Alzheimer’s Disease Cooperative Study (ADCS)
tested 45 ADL items for use in AD clinical trials and
found 27 to be widely applicable for assessment of func-
tional capacity across a wide spectrum of severity [25].
The 19-item version (ADCS-ADL19), covering mainly
basic ADL, is used for the assessment of patients with
more severe AD, while the 23-item version (ADCS-
ADL23) includes more complex ADL for the assessment
of mild to moderate AD, such as reading books or
magazines, pastime activities, or household chores. Rat-
ings take about 20 minutes and are based on informa-
tion obtained from the patient and caregiver. The scores
range from 0 to 78, higher scores indicating less func-
tional impairment. Another AD-specific and commonly
used scale for functional assessment is the Disability
Assessment for Dementia [26]. Based on an interview
with the caregiver, the clinician evaluates whether the
patient needs support concerning initiation, organization
and planning, and effective performance in 10 areas of
functioning, including basic, instrumental, and leisure
daily activities. Other functional instruments used in dif-
ferent clinical settings for assessment of AD patients are
the Interview for Deterioration in Daily Living Activities
in Dementia [27], the Functional Autonomy Measure-
ment System [28], and the Rapid Disability Rating Scale
[29]. The Bayer Activities of Daily Living Scale (B-ADL)
was developed for patients with mild cognitive impair-
ment or mild to moderate dementia to measure deficits
in the performance of everyday activities [30]. It is a
useful tool for evaluation of treatment effects and the
progress of dementia in general practice primary care.
Other functional instruments particularly used for
patients with mild cognitive impairment are the Activ-
ities of Daily Living-Prevention Instrument [31], devel-
oped to rate ADL in prevention of dementia studies,
and the Functional Assessment Questionnaire [32]. A
recent review of the IADL scales has pointed to a need
for an improvement in the psychometric properties of
the currently available IADL instruments in order to
justify better their usefulness in clinical practice [33].
Global impression
The concept of Clinical Global Impression (CGI) for
evaluation of pharmacological treatment effects was
introduced by Guy, 1976 [34]. The CGI scales rely on
Table 2 Identified instruments for assessment of AD symptoms (Continued)
GDS Geriatric Depression Scale [48] Yesavage et al. 1983
HoNOS 65+ Health of the Nation Outcome Scale for Elderly People [90] Burns et al. 1999
NPI Neuropsychiatric Inventory [42] Cummings et al. 1994
NRS Neurobehavioral Rating Scale [91] Sultzer et al. 1995
RMBPC Revised Memory and Behavior Problems Checklist [92] Teri et al. 1992
Quality of Life ADRQL Alzheimer Disease Related Quality of Life [57] Rabins et al. 1999
DQoL Dementia Quality of Life Instrument [58] Brod et al. 1999
DS-DAT Discomfort Scale for Dementia of Alzheimer’s Type [64] Hurley et al. 1992
OERS Observed Emotion Rating Scale [93] Lawton et al. 1999
PDS Progressive Deterioration Scale [62] DeJong et al. 1989
QoL-AD Quality of Life-Alzheimer’s Disease [59,60] Logsdon et al. 1999
QUALID Quality of Life in Late-Stage Dementia Scale [61] Weiner et al. 2000
Communication/
Social
CLB Core Linguistic Battery [94] Bayles et al. 1992
Interaction CPS Communication Problems Scale [66] Powell et al. 1995
ERT Emotion Recognition Test [95] Shimokawa et al. 2000
MOSES Multidimensional Observation Scale for Elderly Subjects [96] Helmes et al. 1987
PKT Posture Knowledge Test [97] Mozaz et al. 2002
PPQSA Partner-Patient Questionnaire for Shared Activities [98] Reilly 2006
SCS Social Competence Scale [99] Zigler & Phillips 1961
Multi-domain BGP Behavioral Rating Scale for Geriatric Patients [71] van der Kam et al. 1971
GBS Gottfries-Brane-Steen Scale [68,69] Gottfries et al. 1982
NOSGER Nurses’ Observation Scale for Geriatric Patients[70] Brunner & Spiegel 1990
SCAG Sandoz Clinical Assessment Geriatric Scale [67] Shader et al. 1974
VL The Vienna List [72] Porzsolt et al. 2004
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Page 5 of 13the clinician’s rating of global severity and/or change in
patient’s clinical condition. Global measures developed
for use in dementia are normally based on a compre-
hensive and (semi-) structured interview with the
patient and other suitable (caregiver-) informants [13].
The scales characterize clinically manifested changes of
dementia, based on a multidimensional evaluation of
cognitive, functional, and behavioral symptoms. The glo-
bal measures selected by our literature search (Table 2)
include global severity scales, such as the Clinical
Dementia Rating [35], the Global Deterioration Scale
[36], and the Functional Assessment Staging [37], and
global change scales, such as the Alzheimer’sD i s e a s e
Cooperative Study - Clinical Global Impression of
Change [38] and the New York University - Clinician’s
Interview Based Impression of Change - Plus Caregiver
Input [39]. The administration time of global assessment
scales ranges from 5 to 45 minutes depending on the
amount of information to be gathered. The main advan-
tage of global measures is that they take into account
multiple domains of real life information and, in con-
trast to performance-based tools such as MMSE, a
detected change in the patient’s condition is clinically
meaningful, as an experienced clinician can detect the
change. On the other hand, most global measures do
not allow separate monitoring of changes over time in
several AD-relevant domains.
Behavior
During the last decades, several instruments have been
developed to assess behavioral and psychological symp-
toms in AD patients. Our literature search identified 15
scales, including instruments for assessment of behavior
and mood. The BEHAVE-AD was developed to assess
behavior in patients with AD apart of cognitive sympto-
matology [40]. It covers symptoms in seven categories:
paranoid and delusional ideation, hallucinations, activity
disturbances, diurnal rhythm disturbances, aggressive-
ness, affective disorders and anxieties, and phobias. The
administration time is about 20 minutes, and behavior is
rated as mild, moderate, or severe. An early developed
instrument for assessment of behavior, which is still
often used in clinical practice and psychopharmacologi-
cal research, is the Brief Psychiatric Rating Scale (BPRS).
It contains 18 items grouped in five factors - depression,
agitation, cognitive dysfunction, hostile suspiciousness,
and psychotic distortion - rated on a seven-point sever-
ity scale [41]. The administration of the BPRS takes 20
minutes by an experienced clinician and is based on
observation of and self-reporting by the patient. Pre-
sently, the most widely used behavior scale in AD is the
Neuropsychiatric Inventory (NPI). It was developed to
compensate for shortcomings of the BEHAVE-AD,
which neglects symptoms related to apathy, irritability,
or disinhibition [42]. The NPI distinguishes between fre-
quency and severity of symptoms; it is informant-based
and requires about 30 minutes for administration. A
brief version was developed, which relies on a question-
naire and assesses only symptom severity [43]. However,
as the NPI contains contradicting opposing symptoms
(euphoria and depression), the value of the NPI total
score has recently been called into question [44] and it
seems more important to look at the scoring of each
behavioral domain.
Other instruments used in clinical settings for rating
behavioral abnormalities in patients with AD are the
Behavior Rating Scale for Dementia of the Consortium
to Establish a Registry for Alzheimer’s Disease [45], the
Dementia Behavior Disturbance Scale [46], as well as
instruments targeting specific behaviors, such as the
Cohen-Mansfield Agitation Inventory [47] for agitation
and aggressiveness, the Geriatric Depression Scale [48]
for depression, and the Apathy Inventory [49]. In addi-
tion, there are instruments designed specifically for
assessment of depression severity and mood changes in
demented patients, such as the Dementia Mood Assess-
ment Scale [50], the Cornell Scale for Depression in
Dementia [51], and the Alzheimer’s Mood Scale [52].
Quality of life
In the second half of the 1990 s, following a general
medical trend of moving away from mainly symptom
treatment towards patient-centered medical care, the
development of scales for assessment of quality of life
(QoL) became a new challenge. Most dementia QoL-
scales refer to Lawton’s model of QoL in dementia
[53]. According to this model, QoL is the result of a
dynamic interaction between four patient-relevant
dimensions: psychological well being, perceived quality
of life, behavior competence, and environment [54].
QoL scales contain aspects not considered in most
conventional scales, such as interpersonal relationships,
self-esteem, living environment, being useful, giving
meaning to life, or financial situation. In general, QoL
instruments are specific to the severity stage of AD
and differ with regard to the domains covered. Most
QoL scales are short and easy to administer. However,
there has been substantial debate whether patients
with AD, especially in more advanced stages, can reli-
ably report on their QoL and whether caregiver reports
are an appropriate alternative [55]. Furthermore, the
individual designation of QoL is rather flexible and
inherently differing among people, which makes the
common understanding of what is important for the
Q o Lo fap e r s o nw i t hd e m e n t i aac h a l l e n g ef o r
researchers and clinicians. To rate the extent to which
treatment goals individually defined by the patient,
caregiver or physicians are achieved, the method of
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both geriatric and dementia populations [56].
Among the QoL scales selected in our search were
the Alzheimer Disease Related Quality of Life
(ADRQL) [57], the Dementia Quality of Life Instru-
ment (DQoL) [58], the Quality of Life - Alzheimer’s
Disease (QoL-AD) [59,60], and the Quality of Life in
Late-Stage Dementia Scale (QUALID) [61]. The
ADRQL is an observer-rated instrument, which mea-
sures positive and negative behavior across five
domains: social interaction, awareness of self, feelings
and mood, enjoyment of activities, and response to
surroundings. It is appropriate to use in daytime activ-
ities settings and is applicable to all stages of dementia.
The DQoL instrument is a 29-item scale designed for
assessment of QoL in mild to moderate demented
patients. Ratings are based on an interview with the
patients and give estimates for positive and negative
affects, feelings of belonging, sense of aesthetics, and
self-esteem. The QoL-AD was developed for both
patients and caregivers to measure QoL in AD, and
can be used for patients with MMSE score > 10. It
includes 13 items providing assessment of mood, phy-
sical health, memory, relationship, self-esteem, and
current situation. Another QoL instrument specifically
designed for AD patients is the Progressive Deteriora-
tion Scale [62]. It is relatively easy to administer, only
10 to 15 minutes to complete, and has been often used
in clinical settings. In addition, the QoL measures
include the Schedule for the Evaluation of Individual
Quality of Life - Direct Weighing (SEIQoL-DW), a
self-rating instrument which allows patients to desig-
nate and weigh the most important domains affecting
their quality of life [63]. Another easy to use but
requiring extensive training for administration instru-
ment is the Discomfort Scale - Dementia of Alzheimer
Type [64]. It is an observation assessment scale devel-
oped to measure discomfort in the elderly with AD.
Communication and social interaction
Improving QoL of AD patients requires specific instru-
ments to assess problems related with the ability of
patients to communicate and interact with others. Com-
munication breakdown in AD results from disturbances
in semantic and linguistic processes or memory deficits
and causes a large number of symptoms. The dimin-
ished ability to communicate leads to a decline in the
quality of social interactions and increased caregiver
burden [65]. Our literature search revealed seven instru-
ments for assessment of symptoms of communication
breakdown. An example for evaluation of semantic and
pragmatic problems in communication with AD patients
is the Communication Problems Scale [66]. It is a 16-
item inventory administered to caregivers, who estimate
the frequency of each communication behavior on a
five-point score.
Selected multi-domain scales
In this study, the literature survey was based on pre-
defined requirements for a multi-domain AD scale for
therapy evaluation in daily medical practice in order to
identify existing AD scales which might cover the cri-
teria, respectively. Most of the selected scales (Table 2)
appear to evaluate aspects which can be predominantly
assigned to a single AD symptom domain, namely cog-
nition, ADL, or behavior, including also a few scales
selected as tools for assessment of patients’ well-being,
affects, apathy, mood, pain, and communication/social
interaction. A number of global and QoL scales were
also identified by the search. In general, conventional
AD symptom domains can not be allocated to QoL
scales. These assessment tools are inherently multidi-
mensional, delivering a subjective patient perspective;
however, they can not replace the detailed evaluation of
function or behavior.
Besides these scales, our literature survey yielded only
a few scales that allow assessment of several AD-
domains (cognition, ADL, behavior, including also com-
munication/social interaction) and cover at least some
of the requirements for a multi-domain instrument for
therapy evaluation in daily medical practice, listed in
Table 1. The selected multi-domain scales are: the San-
doz Clinical Assessment Geriatric (SCAG) [67], the
Gottfries-Brane-Steen (GBS) [68,69], the Nurses’ Obser-
vation Scale for Geriatric Patients (NOSGER) [70], the
Behavioral Rating Scale for Geriatric Patients (BGP)
[71], and the Vienna List [72]. Table 3 provides a brief
overview on the AD-domains covered by the scales, the
patient population, scale administration and application.
The SCAG is a general-purpose rating scale to assess
changes following treatment. It contains 18 items, com-
prising the assessment of agitation, cognitive dysfunc-
tion, depressed mood, and withdrawal, scored on a
seven-point scale. An additional item, item 19 of the
SCAG, is included for global severity rating. A skilled
clinician administers the scale over 15 to 30 minutes.
Rating is based on observed behavior and not on the
patient’s own impression. The SCAG was designed spe-
cifically for evaluation of pharmacotherapy in senile
dementia and for a time was widely used as an outcome
measure in drug research [73].
The GBS was designed to measure the degree of
dementia and to profile dementia syndromes. It consists
of 26 items divided into four subscales measuring motor
performance, intellectual disturbances, and emotional
impairment; the fourth subscale, entitled self-care, esti-
mates different dementia symptoms’ characteristics over
time, comprising the assessment of confusion,
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Page 7 of 13irritability, agony, anxiety, mood, and restlessness. Only
trained clinicians (physicians, psychologists and nurses)
can administer it. The rating takes about 30 minutes
and is based on observation of the patient during a
semi-structured interview. The scale is not meant for
diagnostic purposes but for repeated measurements of
patients participating in clinical trials and evaluation of
drug treatment effects.
T h eN O S G E Ri sar a t i n gs c a l et h a tc o v e r saw i d e
range of behavioral pathology relevant to daily function-
ing and independent of gender or social status of the
patients [70]. It consists of 30 items which measure
impairment in the following areas: memory, IADL, basic
ADL, mood, socialization, and disturbing behavior. Each
item is rated on a five-point scale according to fre-
quency of occurrence. Rating takes about 20 minutes
and is based on direct observation of daily behavior by
the nurse/caregiver over a two-week period. The scale
was developed for rating the frequency of behavioral dis-
turbances, but appears suitable for dementia screening
as well. Validation studies have shown good acceptance
of the scale, high inter-rater and test-retest reliability,
and high correlations of NOSGER dimension scores
with results of other scales [70].
Distinct from the first three multi-domain scales, the
BGP is predominantly a scale for behavioral assessment
of geriatric patients. It has been used in Europe since
1971 and has demonstrated good reliability in measuring
longitudinal changes. Thirty-five items are included in
the BGP, covering aspects of cognition, function, and
behavior. The BGP-Care dependency subscale (nine
items) is particularly used for assessment of cognitive
and functional characteristics associated with increased
need for care. The rating is based on observed behavior
for a week by the clinical nursing staff. The scores range
from 0 to 70, higher scores reflecting increased severity.
In contrast to the BGP, the Vienna List is a relatively
new instrument. It has been developed as a proxy-rating
measurement for QoL in patients with severe dementia
[72]. The scale consists of 40 items grouped into five
factors describing behavior of demented patients. The
scale has also been validated as a useful, differentiating,
and practical tool for documentation of the outcome of
geriatric inpatient rehabilitation [74].
Each of the identified five multi-domain scales was
compared with the requirements listed in Table 1 to
reveal its relevance to daily medical practice. It shows
that only one of the selected scales, the GBS, is applic-
able to all AD severity stages (mild to severe). The
SCAG can also differentiate between four groups of
individuals: healthy, minimum dementia, depression,
and severe dementia. However, SCAG was developed
for evaluation of the most common clinical manifesta-
tions of geriatric dysfunction and is not specific to pro-
blem behaviors common among patients with AD. The
NOSGER is applicable only for mild to moderate AD
Table 3 Brief overview of the selected multi-domain AD scales
Scale Domains/dimensions
(number of items)
Patient
population
Rating Rater Item
scoring
Application
BGP
(van der
Kam et
al. 1971)
Caregiver dependency (9), Social
skills (7), Aggressiveness (5),
Psychoorganic syndrome (11),
Depressiveness (3)
Moderate
to severe
AD
Observation Nurse,
Caregiver
3-point Used in clinical trials for assessment of
behavior in psychogeriatric patients; the BGP-
care dependency subscale reflects cognitive
and functional characteristics related with
increased need for care
GBS
(Gottfries
et al.
1982)
Intellect (11), Emotion (3), Self-care
(6), Behavior (6)
Mild to
severe AD
Observation/
interview
Physician,
Psychologist,
Nurse
7-point Global assessment tool for evaluating
dementia symptoms; it is not suitable for
diagnostic purposes but for repeated
measurements of patients participating in
clinical trials for assessment of drug treatment
effects
NOSGER
(Brunner
& Spiegel
1990)
Memory (5), IADL (5), Self-care (5),
Mood (5), Social behavior (5),
Disturbing behavior (5)
Mild to
moderate
AD
Observation Nurse,
Caregiver
5-point Developed for longitudinal studies in
psychogeriatrics; used in several European and
North American centers; suitable for dementia
screening
SCAG
(Shader
et al.
1974)
Cognitive dysfunction (4),
Interpersonal relationship (4),
Apathy (4), Affect (3), Somatic
function (3)
Senile
dementia
Observation/
interview
Clinician 7-point General-purpose rating scale developed for
evaluation of pharmacotherapy in senile
dementia; widely used in drug research trials
during 1980’s
VL
(Porzsolt
et al.
2004)
Communication (15), Negative
affect (10), Bodily contact (5),
Aggression (4), Mobility (6)
Severe AD Observation Physician,
Nurse
7-point A relatively new developed proxy-rating QoL
instrument for documentation of the outcome
of geriatric inpatient rehabilitation
AD, Alzheimer’s disease; BGP, Behavioral Rating Scale for Geriatric Patients; GBS, Gottfries-Brane-Steen; NOSGER, Nurses’ Observation Scale for Geriatric Patients;
SCAG, Sandoz Clinical Assessment Geriatric; VL, the Vienna List
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Page 8 of 13patients, whereas the BGP and the Vienna List are
designed for moderate to severe and severely demented
patients, respectively.
All the scales were reported as easily administrable
and practical for use, requiring a relatively short time
for administration. However, both the BGP and the
Vienna List appear a bit lengthy (35 and 40 items,
respectively). For comparison, the patient and caregiver
versions of the 13-item QoL-AD scale can be completed
on average in 10 minutes [59]. Two of the scales, the
NOSGER and the BGP, are based on observations taken
by nurse/caregiver, whereas the other three scales are
based on observations by a trained clinician. Validation
data (inter-rater, test-retest, construct and concurrent
reliability) are published for all selected scales. Most of
the scales have shown a good sensitivity to measure
changes with disease progression. The SCAG and GBS
have also proven their reliability in monitoring treat-
ment effects over time.
A common disadvantage of all five scales is the
emphasis given to the assessment of a single AD-symp-
tom domain despite the scales’ multi-domain structure.
Particularly, the assessment of behavior is prevailing in
the NOSGER, BGP, and the Vienna List, whereas the
cognitive evaluation is central to the GBS and SCAG
scales.
The GBS is applicable to all AD severity stages but its
disadvantage is the inclusion of only basic ADL, which
can lead to ceiling effects in mild AD patients. Also, no
IADL are scored and QoL is not assessed. Furthermore,
the GBS contains only one language item (language dis-
turbances) while the NOSGER, BGP, and the Vienna
List, which were developed on a more caregiver-based
perspective, also take into account aspects related to
social interaction. For example, the NOSGER contains
items such as “is interested in what is going on around
him/her”, “helps others as far as physically able”,o r
“when asked questions, seems quarrelsome and irrita-
ble”. Unfortunately, these scales have limitations con-
cerning the severity AD stage to which they can be
applied.
Development of a new multi-domain AD scale
Despite the variety of validated AD-scales revealed by
our literature survey, none of the selected instruments
fulfilled all criteria for a multi-domain AD scale given in
Table 1. The development of a new instrument that can
address multiple domains at all stages of AD severity
while remaining sensitive to changes and therapy effects
seems to be an ambitious goal. To achieve it, the
approach of combining available AD scales appears to
be inappropriate as these scales have different designs
and scopes of assessment. Hence, we believe that the
new multi-domain instrument should be developed with
a novel design that may best serve primary care physi-
cians to assess severity of AD symptoms, disease pro-
gression, and therapy effects in daily medical practice.
How should such a scale be created and used in prac-
tice? First of all, practice-relevant endpoints that cover a
broad spectrum of AD symptoms and enable global
clinical evaluation of the disease progression should be
selected and included in an appropriate test-frame
applicable to all disease severity stages. We believe that
an external assessment carried out by a medical practi-
tioner and based on an interview with the patient and/
or patient’s caregiver would be the most appropriate for-
mat for the new practical instrument. Given the broad
disease severity range of the scale, special attention
should be given to eventual floor and ceiling effects,
which can compromise the measurement. Ceiling effects
may be expected for patients in the early AD stage;
therefore, we would propose developing the scale only
for assessment of patients with clearly established diag-
nosis of AD and exclude prodromal stages of dementia,
such as mild cognitive impairment. Another challenge is
the development of a test-frame applicable to a broad
scope of AD patients differing in terms of cultural back-
ground. This may be achieved by using a scale allowing
adjustments to individual patients without loosing sensi-
tivity and reliability. An interview based on a given
example of event or action, that is, scenario, for assess-
ment of AD symptoms would be an appropriate test-
format; thus, alternative scenarios could be adapted to
the individual patient. Validated translations in many
languages would also be required. Besides being a reli-
able and sensitive tool, such a scale should also be user-
friendly to become often used in daily clinical practice.
We assume the new scale for clinical practice should
take about 15 to 30 minutes for administration by an
experienced clinician, who is supposed to be familiar
with the background clinical information of the patient.
At following assessments, such a scale would enable the
user to obtain and evaluate data faster and at ease. For
accurate assessment, the clinician should use a broad
source of information about the patient, for example,
from a caregiver, a relative, or the patient himself.
Accordingly, an informant interview would be an appro-
priate form of administration.
Altogether, the development of the new instrument
would require considerable effort, combining the knowl-
edge and experience of primary care clinicians, research-
ers, and caregivers from different countries. As a first
step towards scale development, a panel meeting with
medical and caregiver experts with long-term experience
in AD therapy was organized to discuss the content of
this new scale and to establish a strategy for scale devel-
opment. In general, a consensus was achieved that most
AD scales commonly used in clinical practice do not
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AD scale. Most are standardized assessment tools to
measure predominantly the severity of major dysfunc-
tion in a particular AD domain, but are not sufficiently
sensitive to all AD stages, therefore are not easily applic-
able for tracking changes in routine medical practice
and comparable in different patient populations. More-
over, several aspects of cognition and communication/
social interaction, which are of great impact for daily
medical practice, appear to be neglected and/or not well
captured by the commonly used AD scales. Cognitive
aspects such as misidentification, learning aptitude, self-
disclosure, decision making, self-determination, and dis-
turbed/slowed response to external stimuli, seem rarely
presented in the selected standard measures. The fol-
lowing aspects of communication and social interaction
were also considered seldom presented in AD scales:
responsiveness, correct use and interpretation of ges-
tures and facial expressions, implementation of com-
mands, cooperation in care and daily living, social
involvement, adaptability, relationships with family/
friends, and intimacy of contacts (informal/formal).
The extensive discussion on these specific practical
challenges contributed to the primary selection of prac-
tice-relevant assessment criteria to be included in the
new scale. In total, 16 items with high clinical relevance
were selected for the new instrument and grouped as
follows: cognition (three items), communication (three
items), behavior (five items), and activity of daily living
(ADL) (three items). Two additional endpoints for glo-
b a lc l i n i c a le v a l u a t i o no fp a t i e n t s ’ quality of life and
caregiver burden were considered relevant as well. As a
next step, a framework appropriate for assessment of
patients at all AD severity stages was developed based
on stage-specific scenarios (early, middle, and late) and
relevant examples for assessment of each scale item. For
an individual patient, the scenario should be chosen by
the clinician as dependent on the clinician’s global
impression of patient’s AD-relevant symptoms and their
severity. Such a test framework enables also the use of
patient-adapted scenarios, which makes it appropriate
for assessment of patients with diverse cultural, social,
or educational backgrounds. Further considerations
regarding test utility were discussed at the panel meet-
ings, leading to the final set up of a clinical trial design
whose primary goal was to evaluate the validity, reliabil-
ity, and sensitivity of the new instrument. This clinical
trial has recently been performed, demonstrating the
validity and reliability of the new instrument. Some of
the clinical trial results have recently been presented at
the 11th International Geneva/Springfield Symposium
on Advances in Alzheimer Therapy [75,76] and will be
published in a separate manuscript currently in
preparation.
Conclusions
Given the literature review results and extensive discus-
sions at the expert panel meetings, a new AD scale
designed for multidimensional assessment of symptoms
in daily medical practice and applicable to all AD sever-
ity stages is definitely needed. Such a scale would serve
experienced clinicians and researchers in monitoring
patient-relevant AD symptoms over time in clinical
practice, and in evaluating the efficacy of new treat-
ments under development. A great advantage of such a
rating tool for clinical practice is the possibility to easily
profile AD-relevant symptoms for a patient, and thus
get a broad overview of a patient’s disease status and
therapy effects over time. Also, such a tool may be used
as a sensitive global measure of changes across severity
stages, and thus provide evaluations of therapy effects in
long-term assessments to caregivers or reimbursement
agencies.
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